



# **EMA multistakeholder workshop on shortages of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Mitigation measures**

Novo Nordisk presentation

01 July 2024

# Novo Nordisk at a glance

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.

We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.



# GLP-1 RAs supply mitigative actions



Manufacturing facilities are  
**operating 24/7**



**Expanding our capacity globally** through internal and external investments, acquisitions and Contract Manufacture Organisations



**Optimising our production processes** in line with regulatory requirements



**Working closely with health authorities** to minimise the impact on patients



Continue our commitment to develop and introduce  
**innovative treatments**



**Maximising the use** of all drug delivery systems

The **safe use** of medicines  
is our top priority.

We are committed to  
**supporting responsible  
use of medicines** within  
the approved indication.

Examples of measures taken:

Posting information on local Novo Nordisk webpages  
if applicable in alignment with local requirements

---

Working with Health Authorities regarding Direct  
Healthcare Professional Communications (DHPC)

